There is a little known company that is changing warfare

With geo - political instability around the world investors are flocking to defense contract stocks. There is a little known company that is changing warfare. With the backing of U.S. government contracts, this startup is reshaping the future of the U.S. military.

Click here to gain instant access to one of the most exclusive pre-ipo opportunities in the market t

Susan Sholtis Biography and Net Worth

President of PetIQ

Ms. Sholtis joined PetIQ as our President in October 2018. Most recently, she served as a Global Marketing Head in the Health Division at Reckitt Benckiser from 2017 until her appointment as President of PetIQ in September 2018; previously Ms. Sholtis served on PetIQ’s board of directors from March 2018 until September 2018. From 2016 to 2017, Ms. Sholtis served as Head of North America Commercial Operations at Merial and was responsible for transitioning North America operations to Merial’s new owner, Boehringer Ingelheim. Prior to that, from 2006 to 2016, Ms. Sholtis served in a number of positions at Mead Johnson Nutrition, most recently as Head of Global Marketing. Previously, Ms. Sholtis also spent eight years at Merial beginning in 1996 where she most recently had global responsibility for managing two of the largest brands in animal healthcare, FRONTLINE® and HEARTGARD®. Ms. Sholtis earned a Bachelor’s degree from Butler University and a Masters of Business Administration from Emory University.

What is Susan Sholtis' net worth?: The estimated net worth of Susan Sholtis is at least $62,114.90 as of May 24th, 2021. Ms. Sholtis owns 2,005 shares of PetIQ stock worth more than $62,115 as of November 17th. This net worth estimate does not reflect any other investments that Ms. Sholtis may own. Learn More about Susan Sholtis' net worth.
How do I contact Susan Sholtis?: The corporate mailing address for Ms. Sholtis and other PetIQ executives is 923 S. Bridgeway Pl., EAGLE ID, 83616. PetIQ can also be reached via phone at (208) 939-8900 and via email at [email protected]. Learn More on Susan Sholtis' contact information.
Has Susan Sholtis been buying or selling shares of PetIQ?: Susan Sholtis has not been actively trading shares of PetIQ during the last ninety days. Most recently, on Friday, December 17th, Susan Sholtis bought 4,750 shares of PetIQ stock. The stock was acquired at an average cost of $20.85 per share, with a total value of $99,037.50. Learn More on Susan Sholtis' trading history.
Who are PetIQ's active insiders?: PetIQ's insider roster includes McCord Christensen (CEO), Robert Herrman (General Counsel), Ronald Kennedy (Director), John Newland (CFO), Susan Sholtis (President), and Michael Smith (EVP). Learn More on PetIQ's active insiders.
Are insiders buying or selling shares of PetIQ?: In the last year, insiders at the sold shares 1 times. They sold a total of 12,117 shares worth more than $268,876.23. The most recent insider tranaction occured on June, 12th when Director Scott Huff sold 12,117 shares worth more than $268,876.23. Insiders at PetIQ own 9.6% of the company. Learn More about insider trades at PetIQ.
Information on this page was last updated on 6/12/2024.

Susan Sholtis Insider Trading History at PetIQ

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/17/2021	Buy	4,750	$20.85	$99,037.50
5/24/2021	Sell	2,482	$41.02	$101,811.64	2,005
3/15/2021	Sell	10,748	$36.04	$387,357.92	15,697
6/14/2019	Sell	291	$29.18	$8,491.38

Susan Sholtis Buying and Selling Activity at PetIQ

PetIQ Company Overview

PetIQ, Inc. operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which sells flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as third-party branded products for dogs and cats. It also provides OTC medications and supplies primarily within the flea and tick control, dog dewormers, and behavior management categories of the health and wellness industry in various forms, such as spot on (topical) treatments, chewables, oral tablets, and collars. In addition, the company offers health and wellness products that include dog and cat treats, oral health solutions, stain and odor treatments, and pet nutritional supplements under the PetArmor®, Rocco & Roxie®, VetIQ®, Minties® and Sentry® brands. It provides its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PurLuv, Rocco & Roxie, Minties, Heart Shield Plus, and TruProfen brand names. In addition, the company operates veterinarian service platform through community clinics, pop-up locations, wellness centers, and permanent locations that offer cost effective and convenient veterinary wellness services, including diagnostic tests, vaccinations, prescription medications, microchipping, grooming and hygiene, and wellness checks; and provides veterinary care services. It operates through veterinarian, retail, and e-commerce channels. PetIQ, Inc. was founded in 2010 and is headquartered in Eagle, Idaho.

Today's Range

Now: $30.98

$30.98

50 Day Range

MA: $30.87

$30.64

$30.99

2 Week Range

Now: $30.98

$15.09

$31.06

Volume

N/A

Average Volume

480,624 shs

Market Capitalization

$925.99 million

P/E Ratio

79.44

Dividend Yield

N/A

Beta

1.73